CClinicalTrials.gg
CompletedNCT06020911Updated May 1, 2024

Indirect Pulp Capping Using Biodentine and Theracal Light-cured in Primary Molars

A Phase 4 interventional study of Biodentine and Theracal light cured in Pulp Caping, Biodentine and Theracal, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2024-05-01.

Sponsored by Tanta University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jan 2023, registered Aug 2023).
Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
4 Years to 7 Years
Sex
All
01

Study summary

this study is aimed to conduct tomographic evaluation of reparative dentin bridges formed after indirect pulp capping with Biodentine and Theracal light cured. The null hypothesis of the study is that there will be no difference in the quantity and quality of reparative dentin formation between the tested materials used for the indirect pulp capping

Read the detailed description

Many materials have been used in indirect pulp capping for primary dentition. An ideal pulp capping material is to be successful when it is biocompatible, radiopaque, maintain good seal, protect the pulp against bacterial invasion in both long and short run, release sustained amounts of calcium ions, act as reservoir for calcium hydroxide and stimulate reparative dentin formation through inducing the pulp cells to form odontoblasts.

Theracal light cured is a light-cured resin modified calcium silicate (RMCS) used as an indirect pulp capping material. It releases more calcium ions than Mineral trioxide aggregate or dycal inducing reparative dentin and dentin bridge formation.Theracal light cured showed better sealing ability and less microleakage than Mineral trioxide aggregate and Biodentine

02

Conditions studied

  • Pulp Caping
  • Biodentine
  • Theracal
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Each child has bilateral vital cavitated carious lesions in primary molars.
  2. Positive vital pulp testing for both hot and cold response; is determined by ethyl chloride in cold pulp testing and heated gutta percha in hot pulp testing. Pain caused by these tests should not persist after the stimulus is removed.
  3. Patient and parent cooperation.
  4. Accessible isolation for the operated tooth with rubber dam.
  5. primary molars with cavitated carious lesion on either occlusal or proximal surface that extend into the dentin .
  6. Availability of remaining dentin thickness over the pulp.
  7. Normal lamina dura and periodontal ligaments. 8 Absence of external and internal root resorption.

Exclusion criteria

Exclusion Criteria:

  1. Spontaneous pain, or persistent swelling or fistula.
  2. Pain with percussion, presence of abscess and pathological mobility.
  3. Uncooperative patient.
  4. Progression of caries lesion to pulp and pulp exposure.
  5. Presence of periapical lesion as abscess, cyst or granuloma.
  6. Unhealthy bony tissues.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Active comparator
    Biodentine

    17 primary second molars of 17 children will be capped with Biodentine.

    Drug: Biodentine

  • Active comparator
    Theracal light cured

    17 primary second molars of 17 children will be capped with Theracal light cured

    Drug: Theracal light cured

Interventions

  • DrugBiodentine

    17 primary second molars of 17 children will be capped with Biodentine

  • DrugTheracal light cured

    17 primary second molars of 17 children will be capped with Theracal light cured

06

What researchers measure

Primary outcomes

  1. Thickness of dentin in mm

    Cone-beam computed tomography(CBCT) scan will be used after placing the capping material once at the start immediately postoperative after restoration and at the end of follow up period after 9 months to evaluate the Thickness of dentin in mm

    Time frame: UP to 9 months postoperatively

  2. Radiodenisty in Hounsfield units

    Cone-beam computed tomography(CBCT) scan will be used after placing the capping material once at the start immediately postoperative after restoration and at the end of follow up period after 9 months to evaluate the Radiodenisty in Hounsfield units

    Time frame: UP to 9 months postoperatively

  3. pulp vitality

    The teeth in each group will be examined clinically after restoration and at the end of the follow up period using vitality tests. Treatment is considered to be successful when pulp remains vital with no signs of pain, no evidence of tooth mobility, normal tooth color, normal gingival health and presence of the restoration intact

    Time frame: UP to 9 months postoperatively

07

Study locations

1 site
  • Tanta University
    Tanta, El-garbia 139, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06020911
Lead sponsor
Tanta University
Responsible party
Alaa Abd Elhameed Abd Elghany (Principle investigator Alaa Abd Elhameed Abd Elghany, Tanta University) — Principal investigator
First posted
Sep 1, 2023
Start date
Jan 30, 2023
Primary completion
Oct 1, 2023
Completion
Oct 1, 2023
Last update
May 1, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion